Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1993-02-09
1999-02-09
Loring, Susan A.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241371, 4241411, 4241331, 53038885, 5303871, 5303881, 5303875, A61K 39395, C07K 1600
Patent
active
058690506
ABSTRACT:
Methods for causing T cell anergy, treating allograft transplant rejection, treating graft versus host disease, and preventing or treating rheumatoid arthritis are presented, the methods comprising co-administration of a molecule that binds to the B7 antigen and an immunosuppressive agent.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4689299 (1987-08-01), Insel et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4886796 (1989-12-01), Eichner et al.
patent: 4923872 (1990-05-01), Kostlan et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5068223 (1991-11-01), Lipsky et al.
patent: 5100899 (1992-03-01), Calne
patent: 5308847 (1994-05-01), Calne
patent: 5330993 (1994-07-01), Armistead et al.
patent: 5434131 (1995-07-01), Linsley et al.
Kuplec-Weglinski et al., Synergistic interactions between anti-interleukin 2 receptor mab and CyA in snesitized rat recipients of cardiac allografts, Trans. Proc, vol. 23(1) pp. 285-286,1991.
Tufveson et al., New immunosupressants: testing and development in animals models and the clinic:with special reference to DSG. Immunol. Rev. vol. 136, pp. 110-109, 1993.
Cosimi, et al., "Use of Monoclonal Antibodies To T-Cell Subsets for Immunologic Monitoring and Treatment in Recipients of Renal Allografts", The New England Journal of Medicine, 305:308-313 (Aug. 6, 1981).
1992 Physician's Desk Reference at pp. 1217-1218, 1447-1448, 2024-2027 and 2332-2333.
Freeman, et al., "B7, A New Member Of The Ig Superfamily With Unique Expression On Activated And Neoplastic B Cells," 143:2714-2722 (Oct. 15, 1989).
Kriegler, et al., "A Novel Form Of TNF/Cachectin Is A Cell Surface Cytotoxic Transmembrane Protein: Ramifications For The Complex Physiology Of TNF," Cell 53:45-53 (Apr. 8, 1988).
Aruffo, et al., Molecular cloning of a CD28 cDNA by high-efficiency COS cell expression System, Proc. Natl. Acad. Sci. (USA), 84:8573-8577 (Dec., 1987).
Aruffo et al., The Lymphocyte Glycoprotein CD6 Contains a Repeated Domain Structure Characteristic of a New Family of Cell Surface and Secreted Proteins, J.Exp. Med., 174:949-952 (Oct., 1991).
Barneveld, et al., Monoclonal Antibodies against Human .beta.-Glucocerebrosidase, Eur. J. Biochem., 134:585-589 (1983).
Boussiotis, et al., Activated human B lymphocyte express three CTLA-4 counterreceptors that costimulate T-Cell activation, Proc. Natl. Acad. Sci. (USA), 90:11059-11063 (Dec., 1993).
Cafiso, et al., Preparation of Unilamellar Lipid Vesicles at 37.degree. C. by Vaporization Methods, Biochem. Biophys. Acta, 649:129-132 (1981).
de Boer, et al., Functional characterization of a novel anti-B7 monoclonal antibody, Eur. J. Immunol., 22:3071-3075 (1992).
de Boer, et al., Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins, J. Immunol. Methods, 152:15-23 (1992).
Dharakul, et al., Immunization with Baculovirus-Expressed Recombinant Rotavirus Proteins VP1, VP4, VP6, and VP7 Induces CD8.sup.+ T Lymphocytes that Mediate Clearance of Chronic Rotavirus Infection in SCID Mice, J. Virol., 65(11:5928-5932 (Nov., 1991).
DiSanto, et al., Generation of anti-human CD8.beta.-specific antibodies using transfectants expressing mixed-species CD8 heterodimers, J. Immunol. Methods, 141:123-131 (1991).
Fleming et al., In situ Expression of a B7-Like Adhesion Molecule on Keratinocytes from Human Epidermis, J. Investigative Dermatology, 101(5):754-758 (Nov., 1993).
Fraser, et al., Regulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28, Science, 251:313-316 (Jan. 18, 1991).
Freedman, et al., Selective Induction of B7/BB-1 on Interferon-.gamma. Stimulated Monocytes: A Potential Mechanism for Amplification of T Cell Activation through the CD28 Pathway, Cell Immunol. 137:429-437 (1991).
Gabizon, et al., Liposomes as In Vivo Carriers of Adriamycin: Reduced Cardiac Uptake and Preserved Antitumor Activity in Mice, Cancer Research, 42:4734-4739 (Nov., 1982).
Gimmi, et al., B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2, Proc. Natl. Acad. Sci. (USA), 88:6575-6579 (Aug., 1991).
Go et al., Anergized T Cell Clones Retain Their Cytolytic Ability, J. Immunol, 150(2):367-376 (Jan. 15, 1993).
Golub, Immunology A Synthesis, pp. 19-20, Sinauer Associates, Inc. (1987).
Haffar, et al., Costimulation of T-Cell activation and virus production by B7 antigen on activated CD4.sup.+ T cells from human immunodeficiency virus type 1-infected donors, Proc. Natl. Acad. Sci. USA 90:11094-11098 (Dec., 1993).
Harding, et al., CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones, Nature, 356:607-609 (Apr. 16, 1992).
Harper, et al., CTLA-4 and CD28 Activated Lymphocyte Molecules are Closely Related in Both Mouse and Human as to Sequence, Message Expression, Gene Structure, and Chromosomal Location, J. Immunol. 147(3):1037-1044 (Aug. 1, 1991).
Hathcock, et al., Identification of an Alternative CTLA-4 Ligand Costimulatory for T Cell Activation, Science, 262:905-911 (Nov. 5, 1993).
Hawrylowicz, et al., Regulation of Antigen-Presentation-I, IFN-.gamma. Induces Antigen-Presenting Properties on B Cells, J. Immunol., 141(12)4083-4088 (Dec. 15, 1988).
Jenkins, et al., Antigen Presentation by Chemically Modified Splenocytes Induces Antigen-Specific T Cell Unresponsiveness in Vitro and in Vivo, J. Exp. Med. 165:302-319 (Feb., 1987).
Jenkins, et al., Allogenic Non-T Spleen Cells Restore the Responsiveness of Normal T Cell Clones Stimulated with Antigen and Chemically Modified Antigen-Presenting Cells, J. Immunol., 140(10)3324-3330 (May 15, 1988).
Jenkins, et al., Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones, Proc. Natl. Acad. Sci. (USA), 84:5409-5413 (Aug., 1987).
June, et al., Evidence for the Involvement of Three Distinct Signals in the Induction of IL-2 Gene Expression in Human T Lymphocytes, J. Immunol., 143(1):153-161 (Jul. 1, 1989).
June et al., T-Cell Proliferation Involving the CD28 Pathway is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression, Mol. & Cell. Biol. 7(12):4472-4481 (Dec., 1987).
Knauf, et al., Relationship of Effective Molecular Size to Systemic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water-soluble Polymers, J. Bio. Chem., 263(29):15064-15070 (Oct. 15, 1988).
Kohler, et al., Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256:495-497 (Aug. 7, 1975).
Kosco-Vilbois, et al., Follicular Dendritic Cells Help Resting B Cells to Become Effective Antigen-presenting Cells: Induction of B7/BB1 And Upregulation of Major Histocompatibility Complex Class II Molecules, J. Exp. Med. 178:2055-2066 (Dec., 1993).
Kubota, et al., Identification and Gene Cloning of a New Phosphatidylinositol-Linked Antigen Expressed on Mature Lymphocytes, J. Immunol., 145(11):3924-3931 (Dec. 1, 1990).
Lenschow, et al., Expression and functional significance of an additional ligand for CTLA-4, Prol. Natl. Acad., Sci. USA, 90:11054-11058 (1993).
Lin, et al., Long-Term Acceptance of Major Histocompatibility Complex Mismatched Cardiac Allografts Induced by CTLA4Ig Plus Donor-Specific Transfusion, J. Exp. Med., 178:1801-1806 (Nov., 1993).
Mueller, et al., Clonal Expansion Versus Functional Clonal Inactivation: A Costimulatory Signalling Pathway Determines the Outcome of T Cell Antigen Receptor Occupancy, Ann Rev. Immunol., 7:445-480 (1989).
Otten et al., Split Anergy in a CD8+ Cell: Receptor-Dependant Cytolysis in the Absence of Interleukin-2 Production, Science, 251:1228-1231 (Mar. 8, 1991).
Poznansky, Biological Approaches to the Controlled Delivery of Drugs: A Critical Review, Pharm. Revs. 36(4):277-336 (1984).
Ra, et al., A macrophage Fc.gamma. receptor and the mast cell receptor for IgE share an identical subunit, Nature, 341:752-754 (Oct. 26, 1989).
Razi-Wolf, et al., Evidence for an additional ligand distinct from B7, for the CTLA-4 receptor, Proc. Natl. Acad
Conroy Leah B.
de Boer Mark
Blackburn Robert P.
Chiron Corporation
Loring Susan A.
Pochopien Donald J.
Savereide Paul B.
LandOfFree
Methods of blocking T-cell activation using anti-B7 monoclonal a does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of blocking T-cell activation using anti-B7 monoclonal a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of blocking T-cell activation using anti-B7 monoclonal a will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1946665